Phase 1 study of AMG 160, a half-life extended BiTE(R) (Bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer Meeting Abstract
| Authors: | Dorff, T.; Rettig, M.; Machiels, J. P.; Lolkema, M.; Autio, K.; Greil, R.; Rottey, S.; Adra, N.; Salvati, M.; Poon, S.; Tan, D.; Jurida, G.; Kouros-Mehr, H.; Fizazi, K.; Tran, B.; Horvath, L. |
| Abstract Title: | Phase 1 study of AMG 160, a half-life extended BiTE(R) (Bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer |
| Meeting Title: | 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Nov 9-14 |
| Meeting Location: | Virtual |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-11-01 |
| Start Page: | A207 |
| End Page: | A208 |
| Language: | English |
| ACCESSION: | WOS:000616665300330 |
| DOI: | 10.1136/jitc-2020-SITC2020.0340 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 340 -- Source: Wos |
